Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03553550 · ClinicalTrials.gov registry record
Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation
A clinical trial, sponsored by Addario Lung Cancer Medical Institute.
- Terminated
- Registry status
- 38
- Enrollment target
NCT03553550 is a clinical trial that was terminated before completion, run by Addario Lung Cancer Medical Institute. The registered enrollment target is 38 participants.
The verdict
NCT03553550 was terminated before completion, sponsored by Addario Lung Cancer Medical Institute.
- TERMINATED
- Registry status
- 38 participants
- Enrollment target
Study Summary
The purpose of this research study is to learn more about changes in cell-free tumor DNA in blood samples, also known as a liquid biopsy, as they relate to treatment and response to treatment.
Interventions
- OTHER biospecimen collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2020-11-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03553550
The ClinicalTrials.gov registry entry for NCT03553550 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Addario Lung Cancer Medical Institute, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which biospecimen collection is the first listed.
NCT03553550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03553550 about?
NCT03553550 is a clinical study titled "Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation". The purpose of this research study is to learn more about changes in cell-free tumor DNA in blood samples, also known as a liquid biopsy, as they relate to treatment and response to treatment.
What is the current status of trial NCT03553550?
This trial is currently terminated. The enrollment target is 38 participants. The study started on 2018-06-01. Estimated completion is 2020-11-15.
What interventions are being tested in trial NCT03553550?
The interventions under investigation include: biospecimen collection (OTHER).
Who is sponsoring clinical trial NCT03553550?
This trial is sponsored by Addario Lung Cancer Medical Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.